Navigation Links
Fetal Heart-Cell Enzyme and Onset of Heart Failure

In almost all forms of heart failure, the heart begins to express genes that are normally only expressed in the fetal heart//. Researchers have known for years that this fetal-gene reactivation happens, yet not what regulates it. Now, investigators at the University of Pennsylvania School of Medicine have discovered that an enzyme important in fetal heart-cell development regulates the enlargement of heart cells, known as cardiac hypertrophy, which is a precursor to many forms of congestive heart failure (CHF).

The study, which paves the way for new targets for treating cardiac hypertrophy and heart failure, appears in an advanced online publication of Nature Medicine.

“It’s as if old programs are being reactivated in a sick heart,” explains senior author Jonathan A. Epstein, MD, the W.W. Smith Endowed Chair for Cardiovascular Research at Penn. “In an adult heart, stresses such as high blood pressure induce the reexpression of a fetal gene program.”

The investigators found that by inhibiting the enzyme HDAC in adult mice the fetal-gene program can be prevented from restarting. “We found that in various mouse models of cardiac hypertrophy and heart failure, treatment with chemical HDAC inhibitors or genetic deletion of HDAC2 prevented the beginning of the downward slide to progressive heart failure,” says Epstein.

HDAC is an enzyme switch that regulates how DNA is packaged inside the cell, and therefore how large groups of related genes are turned on and off. During development HDAC normally regulates proliferation of heart cells in the embryo. “This makes sense if a molecular pathway in which HDAC has a major role is re-expressed--the adult heart instead makes the cells it already has bigger since it is unable to make more cells very easily.”

The researchers also found that HDAC works in the heart in part by regulating expression of another enzyme called Inpp5f, which is involved in a pathway that contro ls the growth and multiplication of cells. Inpp5f is also related to tumor-suppressor genes involved in cancer.

“HDAC and Inpp5f give us new targets for regulating cardiac hypertrophy,” says Epstein. “Inhibitors of HDAC may warrant testing for cardiac disease to stop the hypertrophy that accompanies the re-expression of the fetal-gene program.” HDAC inhibitors are already in trials for cancer and one, valproic acid, has been used for years to treat seizures. Most CHF medications are aimed at regulating blood pressure, but very few are targeted at the heart-muscle cells themselves. About 5 million Americans are living with CHF today, according to the American Heart Association.

“To understand how to better treat heart disease at the cellular level is an important next step,” says Epstein.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Fish Found To Improve Fetal Growth
2. Fetal Cell Transplant Found To Improve Movement In Patients With Parkinson’s Disease
3. Vitamin Supplements During Pregnancy to Boost Fetal Development
4. Worried About The Sensitive Skin Of Your 2 Year Old? Fetal Skin Cells To Offer Help
5. Using Eyes As The Line Of Reference For Fetal Brain Imaging
6. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
7. Genetic Disorders, Not Fetal Distress Increase Cerebral Palsy Risk
8. Fetal Development Face The Threat By Frequent Ultrasounds
9. New Drug Could Prevent Fetal Alcohol Syndrome
10. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
11. Epilepsy Drug Poses High Risk for Fetal Death and Birth Defects
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows Regional ... – Somers Point, NJ. The new clients range in bed size from 57 to ... solution and its interoperability. , Houston Methodist is a leading academic medical center comprised ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced by Prox Formulas ... and dedicated athletes, continues to transform the nutritional supplement industry by providing a safe, ... protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute officially starts ... 8-night special intensive summer training camp starts on June 17th on Shaolin Institute ... and children a fun and unique experience with an opportunity to learn KungFu ...
(Date:5/29/2016)... ... ... "With 30 unique self-animating web themed intros and complete control over customization, ... Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume 3 ... Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a sleek ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology: